IDEXX Acquires CoVetAI to Enhance Pet Diagnostic Sales with AI Scribe
On September 16, IDEXX Laboratories (NASDAQ: IDXX) announced the acquisition of CoVetAI, a veterinary software company known for its AI-powered scribing tool. The move aims to integrate this technology into IDEXX's existing cloud-based practice management system used by over 10,000 clinics globally. By capturing and organizing patient data during appointments, the tool is expected to streamline workflows and encourage more diagnostic testing. IDEXX reported a second-quarter revenue growth of 10%, with its recurring diagnostics business rising 11%. The company also placed over 1,600 inVue Dx analyzers this quarter. However, without disclosed deal terms or immediate financial impact from the acquisition, it remains unclear how much CoVetAI will contribute to earnings. The stock currently trades at a forward P/E of 30.86 and has low short interest (3.04% of float), indicating strong investor confidence despite potential risks if results fall short.
Tickers: $IDXX
Topics: AI Company strategy Software integration Veterinary diagnostics